Rexulti Tablet
Product Images NDC 70518-4608

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Rexulti (NDC 70518-4608). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

This is a description of Rexulti Tablet, containing the active ingredient Brexpiprazole in a 1 mg dosage. The tablet is round, yellow in color, and comes in a pack of 1 tablet. The tablet is manufactured by Otsuka Pharma Co., Ltd in Tokyo, Japan. The product is repackaged by RemedyRepack Inc., based in Indiana, PA. The usual dosage information is available in the insert. It is recommended to store the medication at 20-25°C (68-77°F), with excursions permitted to 15-30°C (59-86°F) as per USP guidelines. Remember to keep this medication out of reach of children.*

FDA Label Image

Mm1 (Rexulti 1mg 70518 4608 00)

Rexulti Tablet in 1 mg strength, containing Brexpiprazole, comes in a box of 50 tablets. The tablets are round and yellow in color. Manufactured by Otsuka Pharma Co., Ltd, Tokyo, Japan, with the lot number and expiration date to be filled in. This medication is repackaged by RemedyRepack Inc. and is for prescription use only. The usual dosage information can be found in the insert. It is essential to keep this medication out of reach of children and store it at a temperature of 20-25°C (68-77°F) with excursions allowed to 15-30°C (59-86°F) as per USP guidelines.*

FDA Label Image

Chemical Structure (Rexulti 01)

FDA Label Image

Figure 1 (Rexulti 02)

This text provides information on the pharmacokinetics of Brexpiprazole, specifically focusing on its measures of fold change and 90% confidence intervals in relation to renal and hepatic impairment. It also mentions a population description, including gender distribution. The document seems to be a scientific report or study about the medication Brexpiprazole.*

FDA Label Image

Figure 2 (Rexulti 03)

This document outlines the pharmacokinetic changes of Brexpiprazole due to various interacting drugs. The fold changes and 80% confidence intervals are provided for measures such as Cmax when interacting with CYP3A4 inhibitors (e.g., Ketoconazole), CYP2D6 inhibitor (e.g., Quinidine), CYP3A4 inducers (e.g., Rifampin), CYP2B6 inhibitors (e.g., Ticlopidine), and gastric pH-altering drugs (e.g., Omeprazole). The text also mentions changes relative to the reference state without any interacting drug.*

FDA Label Image

Figure 3 (Rexulti 04)

This text provides information on the Effecton maye K Fold Change and 90% confidence intervals for various measures related to the substrates and interactions with different drugs in CYP2D6, PP, VP28, CYP3M, and BCRP pathways. It includes details on substrates such as Urine DHXIDX, Dextromethorphan rato, Fenclenadine, Fexoleradine, Buproion, Lovastatn, Crex, Logsaan, Hydoy Add et, Rosuastatn S, and Rosuastatn A. The data also includes specific values for 0.25, 0.5, 1, 2, and 4 related to changes relative to the reference without interacting drugs.*

FDA Label Image

Figure 4 (Rexulti 05)

FDA Label Image

Figure 5 (Rexulti 06)

FDA Label Image

Figure 6 (Rexulti 07)

FDA Label Image

Figure 7 (Rexulti 08)

FDA Label Image

Figure 8 (Rexulti 09)

This text contains information on the LS mean change from baseline for patients taking either placebo or A REXULTI at different doses. The data includes the number of patients in each group and the time in weeks. It seems to be part of a clinical trial or study.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.